KR20010046778A - Polymer obtained from Phellinus linteus basidiocarp and mycelial and process for preparation thereof - Google Patents
Polymer obtained from Phellinus linteus basidiocarp and mycelial and process for preparation thereof Download PDFInfo
- Publication number
- KR20010046778A KR20010046778A KR1019990050682A KR19990050682A KR20010046778A KR 20010046778 A KR20010046778 A KR 20010046778A KR 1019990050682 A KR1019990050682 A KR 1019990050682A KR 19990050682 A KR19990050682 A KR 19990050682A KR 20010046778 A KR20010046778 A KR 20010046778A
- Authority
- KR
- South Korea
- Prior art keywords
- mycelium
- polysaccharide
- mushroom
- phellinus linteus
- activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G18/00—Cultivation of mushrooms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Environmental Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
본 발명은 상황버섯(Phellinus linteus) 자실체와 균사체로부터 얻은 다당체 및 그 제조방법에 관한 것이다. 더욱 상세하게는, 본 발명은 상황버섯 자실체와 균사체로부터 추출 분리한 면역활성이 우수한 다당체 및 그 제조방법에 관한 것이다.The present invention relates to a polysaccharide obtained from Phellinus linteus fruiting body and mycelium, and a method for producing the same. More specifically, the present invention relates to a polysaccharide excellent in immunological activity extracted and isolated from Prunus mushroom fruiting bodies and mycelium, and a method for producing the same.
면역계를 자극하여 항암효과나 숙주 저항에 영향을 미치는 면역증강물질에 대한 연구가 고등식물(higher plant), 고등균류(higher fungi), 미생물(bacteria), 조류(algae) 등으로부터 조사되어져왔다(Franz, 1989). 이중에서도 특히 버섯류(basidiomycetes)로부터 생산된 다당체에 관한 많은 연구가 진행되고 있다. Ikekawa 등(1968)에 의하여 polyporaceae(말굽버섯과)를 위시하여 식용균류의 자실체를 열수추출하여 얻은 추출물(extract)이 sarcoma 180 등의 동물 이식암에 대하여 숙주 중개성이 현저한 항종양 활성이 있는 것이 발견되었다. 일예로 표고버섯으로부터 Lentinan(Chihara 등, 1970), 치마버섯으로부터 Schizophyllan(Tabata 등, 1981), 운지로부터 Krestin(Tsukagoshi와 Ohashi, 1974), 상황버섯으로부터 Meshima(Han 등, 1995)와 같은 다당체는 현재 항암 및 면역요법제 등으로 널리 사용되어지고 있다.Research on immunopotentiators that stimulate the immune system and affect anticancer effects or host resistance has been investigated from higher plants, higher fungi, bacteria, algae, and others (Franz). , 1989). In particular, many studies are being conducted on polysaccharides produced from mushrooms (basidiomycetes). Ikekawa et al. (1968) show that the extract obtained by hydrothermal extraction of fruiting bodies of edible fungi, including polyporaceae, has significant anti-tumor activity against host transplantation against animal transplant cancers such as sarcoma 180. Found. Polysaccharides such as Lentinan (Chihara et al., 1970) from shiitake mushrooms, Schizophyllan (Tabata et al., 1981) from skirt mushrooms, Krestin (Tsukagoshi and Ohashi, 1974) from fingering, and Meshima (Han et al., 1995) from situation mushrooms are currently It is widely used as an anticancer and immunotherapy agent.
상황버섯 또는 목질진흙버섯(Phellinus linteus)의 자실체 열수추출물은 소화기 계통의 암에 저지효과(Ikekawa, 1968)와 간암, 환자절제 수술후 화학요법 병용에 의한 면역기능 항진이 있는 것으로 나타나 많은 연구가 진행되어 왔으며, 균사체 배양 추출물로부터 면역 활성 (Lee 등, 1996) 및 항암 활성(정 등, 1993)도 입증되었다. 상황버섯에서 추출된 다당체의 항종양작용에 대한 기작은 확실히 밝혀지지 않았으나, 이들이 주로 대식세포(macrophage)나 보체 시스템(complement system) 등의 면역체계를 활성화시켜 항종양 효과를 나타내는 것으로 보고 되고 있다(Suzuki 등, 1989). 특히, Okuda 등(1973)은 항종양활성과 혈청 용혈성(serum hemolytic activity)의 손실이 밀접한 관계가 있음을 입증하여, 보체계 성분의 활성화가 항종양 작용에 관여함을 관찰하였다.Fruiting hot water extracts of Phellinus linteus ( Phellinus linteus) have been shown to have an anti-immune effect due to the combination of chemotherapy after surgery for liver cancer and patient resection with Ikekawa (1968). Immune activity (Lee et al., 1996) and anticancer activity (Jeong et al., 1993) have also been demonstrated from mycelial culture extracts. The mechanism of anti-tumor activity of polysaccharides extracted from situational mushrooms is not clear, but it is reported that they exhibit anti-tumor effects mainly by activating the immune system such as macrophage or complement system. Suzuki et al., 1989). In particular, Okuda et al. (1973) demonstrated a close relationship between antitumor activity and loss of serum hemolytic activity, and observed that activation of complement system components was involved in antitumor activity.
자연으로부터 채취한 상황버섯의 생리활성에 대한 연구로써 Ikekawa (1968)는 자실체 열수 추출물이 소화기계통의 암에 저지효과가 탁월함을 보고하였으며 이는 세포 매개성 면역반응을 촉진 (Maeda and Chihara, 1971)시키거나 면역력이 저하된 암환자의 항체생성능력을 회복 (Nomoto 등, 1975)시킴으로써 항암효과를 나타내는 것으로 알려졌다. 그러나 자연산의 상황버섯은 채취가 쉽지 않으며 품질의 균일성이 확보되지 않은 관계로 상기 버섯의 인공재배 필요성이 대두 되어 왔던 바, 근래에 인공재배에 성공하여 활용 가능성이 증대되고 있다(Song 등, 1997). 또 액체배양으로부터 생산된 상황버섯의 균사체를 열수추출하여 획득한 균체내다당 (endo-polymer)의 항암활성 (Chung 등, 1993)이나 면역활성 (Kim 등, 1996)에 대한 연구가 최근에 진행되어 왔다. 그러나, 아직까지 인공재배 상황버섯과 자연상황 버섯의 자실체 열수 추출 다당체의 면역활성을 조사하여 비교한 연구는 없었으며, 액체배양에 의한 균체내 다당 (endo-polymer) 및 균체외 다당 (exo-polymer)의 면역활성에 대한 비교연구는 보고된 바 없었다.As a study on the physiological activity of natural mushrooms from nature, Ikekawa (1968) reported that fruiting hot water extracts were superior to the cancers of the digestive system, promoting cellular mediated immune responses (Maeda and Chihara, 1971). Or anti-cancer effects by restoring the antibody-producing ability of cancer patients with reduced immunity (Nomoto et al., 1975). However, since natural mushrooms are not easy to be harvested and quality uniformity has not been secured, the necessity of artificial cultivation of these mushrooms has emerged. ). In addition, studies on the anticancer activity of endo-polymers (Chung et al., 1993) and immunological activities (Kim et al., 1996) obtained by hydrothermal extraction of mycelium from situational mushrooms have been recently conducted. come. However, there have been no studies comparing the immunological activity of the fruiting body hydrothermal extract polysaccharides of artificial cultivated mushrooms and natural mushrooms, and endo-polymer and extracellular polysaccharide (exo-polymer) by liquid culture. No comparative studies have been reported on the immunological activity of).
본 발명자들은 자연으로부터 채취한 상황버섯 자실체로부터 얻은 다당체와 인공재배한 상황버섯 자실체로부터 얻은 다당체의 면역활성을 측정하여 비교하므로써 자연산 상황버섯의 대체용으로 인공재배한 상황버섯의 이용성을 조사하고 또 액체배양하여 얻은 상황버섯 균사체의 균체내 다당과 균체외 다당의 면역활성을 측정하여 균사체의 이용성도 조사하므로써 달성하였다.The present inventors investigated the availability of artificially grown situational mushrooms as a substitute for natural situational mushrooms by measuring and comparing the immunological activity of polysaccharides obtained from natural state fruiting bodies and those obtained from artificially grown situational fruiting bodies. The fungal mycelium obtained by cultivation was measured by measuring the immune activity of the mycelial polysaccharide and the extracellular polysaccharide.
따라서, 본 발명의 목적은 상황버섯 자실체와 균사체로부터 추출 분리한 다당체를 제공함에 있다. 본 발명의 다른 목적은 상기 다당체의 제조방법을 제공함에 있다.Accordingly, an object of the present invention is to provide a polysaccharide extracted and separated from the situation mushroom fruiting body and mycelium. Another object of the present invention to provide a method for producing the polysaccharide.
본 발명의 상기 목적은 인공배양한 상황버섯 자실체와 자연에서 채취한 상황버섯 자실체로부터 다당체를 회수하고 같은 방법으로 액체 배양한 상황버섯 균사체부터 균체내 다당체와 균체외 다당체를 얻은 후 상기 각 다당체의 항보체활성을 측정하므로써 달성하였다.The object of the present invention is to recover the polysaccharides from the artificial mushroom cultured fruiting body and the situation mushroom fruiting body collected in nature and to obtain the in-cell polysaccharide and the extracellular polysaccharide from the liquid mushroom cultured mycelium in the same manner, and then This was achieved by measuring complement activity.
이하, 본 발명의 구성 및 작용을 설명한다.Hereinafter, the configuration and operation of the present invention.
도 1은 인공배양한 상황버섯 자실체로부터 다당체를 추출분리하는 과정을 나타낸다.Figure 1 shows the process of extracting and separating the polysaccharides from the artificial cultivated situation mushroom fruiting body.
도 2는 액체배양한 상황버섯 균사체로부터 균체내 다당체 및 균체외다당체를 추출분리하는 과정을 나타낸다.2 shows a process of extracting and separating the intracellular polysaccharides and the extracellular polysaccharides from the liquid cultured mycelium mycelium.
상황버섯 균사체를 배양하다가 색이 황갈색에서 검은색으로 변하면 자실체 재배사로 옮겨 버섯 발생을 유도하여 상황버섯을 인공배양하는 단계; 상황버섯 균사를 PDA 배지에서 배양한 후 합성배지를 이용해 액체 배양하여 균사체를 얻는 단계; 인공배양한 상황버섯 자실체를 열수추출하고 원심분리한 후 동결건조, DIW 용해, 다시 원심분리를 행하여 인공배양한 상황버섯 자실체로부터 다당체를 얻고, 액체 배양한 상황버섯 균사체는 먼저 원심분리하여 균사체 부분과 상층액 부분을 나눈 후 균사체 부분을 에탄올 추출, 원심분리, 동결건조, DIW 용해 및 원심분리하여 균체내 다당류를 얻고, 상층액 부분을 에탄올 침전, 원심분리, 동결건조, DIW 용해, 원심분리하여 균체외 다당체를 얻는 단계 및; 상기 단계에서 얻은 자실체 다당체, 균체내 다당체, 균체외 다당체의 항보체 활성을 Mayer 법에 의해 측정하는 단계로 구성된다.Cultivating the situation mushroom mycelium, when the color is changed from yellowish brown to black, moving to fruiting body cultivator to induce mushrooms to artificially culture the situation mushroom; Cultivating the situation mushroom hyphae in PDA medium to obtain liquid mycelium by liquid culture using a synthetic medium; Hot water was extracted from the artificial mushroom cultured fruiting bodies, centrifuged, and then lyophilized, DIW dissolved, and centrifuged again to obtain polysaccharides from the artificial cultured fruiting mushrooms. After dividing the supernatant, the mycelium part was extracted with ethanol, centrifugation, lyophilization, DIW dissolution and centrifugation to obtain polysaccharides in the cells, and the supernatant part was subjected to ethanol precipitation, centrifugation, lyophilization, DIW dissolution and centrifugation. Obtaining an extracorporeal polysaccharide; It consists of measuring the anti-complement activity of the fruiting body polysaccharide, intracellular microsaccharides, extracellular polysaccharide obtained in the above step by the Mayer method.
본 발명에서 자실체의 인공배양에 사용된 상황버섯(Phellinus linteus)은 강원도 홍천에서 채취하여 순수분리하고 동정하였다(Song 등, 1997). Phellinus linteus ( Phellinus linteus) used in the artificial culture of fruiting bodies in the present invention was collected from Hongcheon, Gangwon-do, and isolated and identified (Song et al., 1997).
본 발명에서 종균보관용 배지로는 PDA(potato dextrose agar;Difco사)를 사용하였으며, 다당체 생산용 배지의 조성은 갈락토오스(Galactose) 1g/L, 슈크로오스(Sucrose) 9g/L, 크실로오스(Xyrose) 1g/L, 글루코스(Glucose) 9g/L, 효모 추출물(Yeast extract) 0.5g/L, 펩톤(Peptone) 2g/L, 감자 덱스트로스 브로스(Patato dextrose broth) 2g/L, NH4H2PO40.5g/L, DL-Serine 0.5g/L, KH2PO41g/L, CaCl20.6g/L, MgSO4ㆍ7H2O 2g/L, FeSO40.02g/L, ZnSO40.02g/L, MnSO40.02g/L, 티아민· HCl 1×10-4/ℓ이었으며, pH는 4.5로 조절하였다.PDA (potato dextrose agar; Difco Co., Ltd.) was used as a medium for seed storage in the present invention, and the composition of the polysaccharide production medium was galactose 1g / L, sucrose 9g / L, xylose (Xyrose) 1g / L, Glucose 9g / L, Yeast extract 0.5g / L, Peptone 2g / L, Potato dextrose broth 2g / L, NH 4 H 2 PO 4 0.5g / L, DL-Serine 0.5g / L, KH 2 PO 4 1g / L, CaCl 2 0.6g / L, MgSO 4 ㆍ 7H 2 O 2g / L, FeSO 4 0.02g / L, ZnSO 4 0.02 g / L, MnSO 4 0.02 g / L, thiamine-HCl 1 × 10 −4 / L and the pH was adjusted to 4.5.
본 발명에서 자실체 배양을 위한 종균배지로는 참나무 톱밥에 미강 10%를 첨가하여 고압멸균한 것을 사용하였으며, 인공재배를 위한 원목은 뽕나무를 기질로 사용하였다.In the present invention, the spawn medium for fruiting body culture was sterilized by adding 10% of rice bran to oak sawdust, and wood for artificial cultivation used mulberry as a substrate.
본 발명에서 사용한 시약중 양의 감작혈구(IgM hemolysin sensitized sheep erythrocyte, EA cell)는 일본 동결건조 연구소로부터 구입하여 사용하였으며, 5,5'-diethylbarbituric acid sodium salt는 Merk사 제품을, 정상인의 혈청(Normal hunman serum, NHS)은 본 발명자가 신선한 상태로 직접 제조하여 사용하였고, 그외 기타 시약은 시판 일급 혹은 특급시약을 사용하였다.IgM hemolysin sensitized sheep erythrocyte (EA cell) in the reagents used in the present invention was purchased from Japan Freeze-Drying Research Institute, and 5,5'-diethylbarbituric acid sodium salt was manufactured by Merk Co., Ltd. Normal hunman serum (NHS) was prepared and used directly by the inventors in a fresh state, and other reagents were commercially available first or express reagents.
이하, 본 발명의 구체적인 방법을 실시예를 들어 상세히 설명하고자 하지만 본 발명의 권리범위는 이들 실시예에만 한정되는 것은 아니다.Hereinafter, the specific method of the present invention will be described in detail with reference to Examples, but the scope of the present invention is not limited only to these Examples.
실시예 1:Example 1: 인공배양에 의한 자실체 생산Fruiting body production by artificial culture
상황버섯(Phellinus linteus)균사체 배양 최적온도는 25℃∼30℃ 이었으나 초기에는 잡균의 발생을 최소화 하기 위하여 21∼22℃로 배양하다가 25∼30일 후 균사체가 원목 전체표면에 활착되어 생장이 시작될 때 부터는 최적온도인 25℃를 유지하였다. 원목의 굵기에 따라 약간의 차이는 있으나 균사체의 색이 황갈색을 띄우다가 검은색으로 변하기 시작하였을 때 (약 2∼3개월) 자실체 생장을 위하여 폴리프로필렌 백(polyprophylene bag)을 해체하고 재배사로 옮겨심기 작업을 하였다. 배양실에서 균사체 배양이 완료된 원목은 윗 표면에 접종원으로 사용한 종균을 완전히 제거한 후 충분히 관수하고 토양에 옮겨 심을 때 지상부로 5∼7㎝정도를 돌출시켜 매몰하여 종균접종을 하였던 상층부에 모래를 얇게 깔아 습도유지와 측면의 버섯발생을 유도하였다.The optimum temperature for mycelial growth of Phellinus linteus was 25 ℃ ~ 30 ℃, but initially it was incubated at 21 ~ 22 ℃ to minimize the occurrence of various bacteria, and after 25 ~ 30 days when mycelium adhered to the whole surface of the logs From 25 ℃ was maintained at the optimum temperature. There are some differences depending on the thickness of the logs, but when the mycelium color starts to yellowish brown and turns to black (about 2 to 3 months), the polypropylene bag is dismantled and transferred to the grower for fruiting. Work was done. After the mycelial culture is completed in the incubation room, the logs are completely watered after removing the spawn seed used as inoculum on the upper surface, and when they are transferred to the soil, they protrude about 5-7cm to the ground and bury them. Induction of fats and oils and flanks.
실시예 2:Example 2: 액체배양에 의한 균사체 배양Mycelial Culture by Liquid Culture
상황버섯(Phellinus linteus) 균사를 PDA배지를 함유한 평판배지상에서 25℃, 10일간 배양 후 직경 8mm cork bore로 펀칭(punching)하여 접종원으로 사용하였고, 액체 배양시에는 합성배지를 이용하여 250㎖ 배플 플라스크(baffled flask)에서 30일간 25℃, 120rpm에서 배양하였다.Situation mushroomsPhellinus linteus) The mycelia were incubated on a plate medium containing PDA medium at 25 ° C. for 10 days, and then punched with 8 mm cork bore in diameter and used as an inoculum. The cells were incubated at 25 ° C. and 120 rpm for 30 days.
실시예 3:Example 3: 자실체 및 균사체로부터 다당체 회수Polysaccharide recovery from fruiting bodies and mycelium
실시예 1에서 인공재배한 상황버섯 자실체와 자연에서 얻은 상황버섯을 열수추출하여 도 1에 나타낸 바와 같이 다당체를 회수하였으며, 실시예 2에서 균사체 액체배양으로 부터의 다당체는 도 2에 나타낸 바와 같이 균체내 다당과 균체외 다당으로 분리하여 회수 하였다. 즉 균사체 액체 배양물을 10447×g/20min으로 원심분리하고, 4℃에서 24시간 침전후 침전물을 원심분리하여 회수하였다. 이를 동결건조한 후 수용성 다당체를 분리하기 위해 10㎎/1㎖(DIW)를 녹여 상등액을 취하여 다시 동결건조하여 시료로 사용하였다.The polysaccharide from the mycelium liquid culture in Example 1 was recovered by hydrothermal extraction of the situation mushroom fruiting body grown in Example 1 and the situation mushroom obtained in nature, as shown in FIG. 2. The polysaccharide and extracellular polysaccharide were separated and recovered. That is, the mycelium liquid culture was centrifuged at 10447 × g / 20 min, and precipitated at 4 ° C. for 24 hours to recover the precipitate by centrifugation. After freeze-drying, 10 mg / 1mL (DIW) was dissolved to separate the water-soluble polysaccharide, and the supernatant was taken and lyophilized again to use as a sample.
실험예 1: 항보체 활성 측정Experimental Example 1 Anti-complement Activity Measurement
항보체 활성은 Mayer법(Kabat and Mayer, 1961)으로 측정하였다. 상기 실시예 3에서 얻은 인공재배한 상황버섯 자실체 다당체(FractionⅠ), 자연에서 얻은 상황버섯 자실체 다당체(Fraction Ⅱ), 액체배양한 상황버섯 균사체로부터 얻은 균체내 다당체(endo-polymer; Fraction Ⅲ), 균체외 다당체(exo-polymer;Fraction Ⅳ) 각각을 시료로 사용하여 이 시료 50㎕씩을 NHS (normal human serum), GVB++(gelatine veronal buffered saline, pH 7.2)와 혼합하여 37℃에서 30분간 반응시킨후 반응액에 GVB++를 350㎕씩 첨가하고, 이를 10배에서 160배까지 연속희석하여 750㎕의 GVB++와 양의 감작혈구(108cells/㎖)를 250㎕씩 첨가하여 1시간동안 반응시킨 다음 PBS(phophate buffered saline, pH 7.4)를 2.5mL씩 가하여 원심분리 후 상등액의 흡광도를 412nm에서 측정하였다. 한편 대조구는 동일조건에서 시료를 함유하지 않은 채 측정하였으며 항보체 활성은 대조구 대비 총보체 용혈 (50% of total complement hemolysis, TCH50)의 저지율 (inhibition of TCH50또는 ITCH50)로 나타내었다. 시료의 정확한 활성을 검정하기 위해 역가를 알고있는 항보체 다당 CAP-0 (ITCH50=61.50%)를 표준물로 하였다.Anti-complement activity was measured by Mayer method (Kabat and Mayer, 1961). Intracellular cultured polysaccharide (Fraction I) obtained in Example 3, in vitro polysaccharide (endo-polymer; Fraction III), microbial polysaccharide (Fraction II) obtained from nature, fruit mushroom polysaccharide (Fraction II), liquid cultured 50 μl of this sample was mixed with NHS (normal human serum) and GVB ++ (gelatine veronal buffered saline, pH 7.2) using each of exo-polymer (Fraction IV) as a sample. After that, 350 μl of GVB ++ was added to the reaction solution, which was continuously diluted from 10 to 160 times, and 750 μl of GVB ++ and 250 μl of positive sensitized blood cells (10 8 cells / ml) were added for 1 hour. After the reaction, PBS (phophate buffered saline, pH 7.4) was added in 2.5 mL portions, and the absorbance of the supernatant after centrifugation was measured at 412 nm. On the other hand, the control group was measured without the sample under the same conditions, and the anti-complement activity was expressed as the inhibition rate of TCH 50 or ITCH 50 compared with the control complement hemolysis (50% of total complement hemolysis, TCH 50 ). In order to assay the correct activity of the sample, anti-complement polysaccharide CAP-0 (ITCH 50 = 61.50%) of known titer was used as the standard.
실험결과, 표 1에 나타낸 바와 같이 자연 상황버섯 자실체 열수추출 다당체의 항보체 활성은 65.77 % 이었으며, 인공재배 상황인 경우는 63.94 %를 나타내어 비슷한 활성도를 보였다. 따라서 면역활성의 측면으로는 인공 상황버섯의 이용가능성이 있음을 나타냈다. 또 표 2에 나타낸 바와 같이 액체 배양한 상황버섯 균체내 다당체와 액체 배양한 상황버섯 균체외 다당체의 면역활성을 비교한 결과, 균체내 추출 다당의 항보체 활성이 41.95 % 그리고 균체외 다당의 항보체 활성이 21.87 %로 보다 높은 활성을 나타내었다.As a result, as shown in Table 1, the anti-complement activity of the natural fruit mushroom fruit water extract polysaccharide was 65.77%, and in the case of artificial cultivation, 63.94% showed similar activity. Therefore, there was a possibility of artificial situation mushroom in terms of immune activity. In addition, as shown in Table 2, as a result of comparing the immune activity of the liquid cultured polysaccharides and the liquid cultured polysaccharides, the anti-complement activity of the extracted polysaccharides was 41.95% and the anti-complex polysaccharides. The activity was higher with 21.87%.
이상, 상기 실시예를 통하여 설명한 바와 같이, 인공배양한 상황버섯 자실체는 자연산 상황버섯 자실체에서 얻은 다당체와 유사한 면역활성을 나타내는 뛰어난 효과가 있고 또 액체배양한 균체내 다당체에서도 상당한 면역활성을 나타내는 효과가 있으므로 생물의약산업상 매우 유용한 발명인 것이다.As described above, the artificial mushroom cultured fruiting body has an excellent effect of showing similar immunological activity as that of the polysaccharide obtained from the natural fruiting fruiting body, and also has the effect of exhibiting significant immune activity even in liquid cultured polysaccharides. Therefore, it is a very useful invention in the biopharmaceutical industry.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990050682A KR20010046778A (en) | 1999-11-15 | 1999-11-15 | Polymer obtained from Phellinus linteus basidiocarp and mycelial and process for preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990050682A KR20010046778A (en) | 1999-11-15 | 1999-11-15 | Polymer obtained from Phellinus linteus basidiocarp and mycelial and process for preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20010046778A true KR20010046778A (en) | 2001-06-15 |
Family
ID=19620186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990050682A KR20010046778A (en) | 1999-11-15 | 1999-11-15 | Polymer obtained from Phellinus linteus basidiocarp and mycelial and process for preparation thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20010046778A (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010000326A (en) * | 2000-09-15 | 2001-01-05 | 박순영 | Use for antitumor agent of extract of Phellinus linteus |
KR20030030636A (en) * | 2001-10-12 | 2003-04-18 | 주식회사 싸이제닉 | Manufacturing method of highly active antitumor protein-polysaccharides using fermentation of the fruit bodies of mushroom |
KR100383078B1 (en) * | 2000-06-16 | 2003-05-12 | 환인제약 주식회사 | Process for mass production of Phellinus linteus by fed-batch culture |
KR20030069454A (en) * | 2002-02-20 | 2003-08-27 | 주식회사한국신약 | Anti-cancer agent comprising polysaccharide obtained from mycelia of phellinus linteus and 5-fluorouracil |
KR100538642B1 (en) * | 2002-06-27 | 2005-12-23 | 이재동 | A Composition for Treating or Preventing Arthritis Containing Acidic Proteo-heteroglycan Extract from Phellinus linteus |
KR101068692B1 (en) * | 2009-01-07 | 2011-09-29 | 박준선 | Immunological functions-improving health food containing ?-glucan derived from Sangwhang mushroom |
KR20220095260A (en) | 2020-12-28 | 2022-07-07 | (주) 비에스티 | A Method for Producing a Vegetable Extract with A Low and Mid Property Enzyme and a Complex Vegetable Composition for an Anti-oxidation and Anti-Browning by the Same |
KR20230081857A (en) | 2021-11-30 | 2023-06-08 | (주) 비에스티 | A Method for Producing an Anti-microbial and Anti-Browning Composition Extracted from a Vegetable Material |
-
1999
- 1999-11-15 KR KR1019990050682A patent/KR20010046778A/en not_active Application Discontinuation
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100383078B1 (en) * | 2000-06-16 | 2003-05-12 | 환인제약 주식회사 | Process for mass production of Phellinus linteus by fed-batch culture |
KR20010000326A (en) * | 2000-09-15 | 2001-01-05 | 박순영 | Use for antitumor agent of extract of Phellinus linteus |
KR20030030636A (en) * | 2001-10-12 | 2003-04-18 | 주식회사 싸이제닉 | Manufacturing method of highly active antitumor protein-polysaccharides using fermentation of the fruit bodies of mushroom |
KR20030069454A (en) * | 2002-02-20 | 2003-08-27 | 주식회사한국신약 | Anti-cancer agent comprising polysaccharide obtained from mycelia of phellinus linteus and 5-fluorouracil |
KR100538642B1 (en) * | 2002-06-27 | 2005-12-23 | 이재동 | A Composition for Treating or Preventing Arthritis Containing Acidic Proteo-heteroglycan Extract from Phellinus linteus |
KR101068692B1 (en) * | 2009-01-07 | 2011-09-29 | 박준선 | Immunological functions-improving health food containing ?-glucan derived from Sangwhang mushroom |
KR20220095260A (en) | 2020-12-28 | 2022-07-07 | (주) 비에스티 | A Method for Producing a Vegetable Extract with A Low and Mid Property Enzyme and a Complex Vegetable Composition for an Anti-oxidation and Anti-Browning by the Same |
KR20230046286A (en) | 2020-12-28 | 2023-04-05 | (주) 비에스티 | A Method for Producing a Vegetable Extract with A Low and Mid Property Enzyme and a Complex Vegetable Composition for an Anti-oxidation and Anti-Browning by the Same |
KR20240002238A (en) | 2020-12-28 | 2024-01-04 | (주) 비에스티 | A Method for Producing a Vegetable Extract with A Low and Mid Property Enzyme and a Complex Vegetable Composition for an Anti-oxidation and Anti-Browning by the Same |
KR20230081857A (en) | 2021-11-30 | 2023-06-08 | (주) 비에스티 | A Method for Producing an Anti-microbial and Anti-Browning Composition Extracted from a Vegetable Material |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1029382C (en) | Method for artificially cultivating north Chinese caterpiller fungus daughter vaccine | |
JP2003081863A (en) | Bioactive substance of mycelium of antrodia camphorata, its compositional substance and method for producing the same | |
JPH01228480A (en) | Production of extract of cultured mycelia of edible basidiomycete | |
KR20010046778A (en) | Polymer obtained from Phellinus linteus basidiocarp and mycelial and process for preparation thereof | |
US2797183A (en) | Nystatin and method of producing it | |
CN111778163A (en) | New russula griseofulva endophytic fungus and application of extract thereof in bacteriostasis | |
KR101833099B1 (en) | Method for producing cordycepin comprising of adding algal or protein medium | |
KR20040047730A (en) | Composition for the culturing of Phellinus linteus mycelium | |
KR100187892B1 (en) | A liquid cultivation of hericicum erinaceus hyphae using by-product of food, and health drink compositions containing hyphae extract thereof | |
KR100398677B1 (en) | Cultivation Method of mushroom mycelium using citrus juice and mushroom mycelium thereof | |
CN103014095A (en) | Use of MetarhiziumtaiiGYYA0601 strain in hyaluronic acid production | |
KR100778943B1 (en) | Cultivation Method of Fomitopsis pinicola Mycelium Using Citrus Peel Extract or Green Tea Extract and Fomitopsis pinicola Mycelium thereof | |
KR100303886B1 (en) | Method for extracting anticancer component from phellinus linteus | |
KR100706132B1 (en) | Composition for the culturing of Phellinus linteus mycelium | |
KR100754821B1 (en) | Method of mass production for mycelia and extracellular polysaccharides of the same cordyceps sphecocephala | |
KR102117227B1 (en) | a phellinus linteus cultivating method using Cudrania tricuspidata and the phellinus linteus | |
EP0939082A1 (en) | Protein polysaccharide 0041 | |
KR20200095208A (en) | Co-culture method of mushroom mycelium | |
JPH0655133B2 (en) | Method for culturing mycelium having anti-cancer effect | |
JPS60190800A (en) | Phytoalexin inducer | |
KR0143512B1 (en) | Immunopotentive agents and isolating methods from cultivated ganoderma lucidum | |
JP3152402B2 (en) | Antitumor agent and method for producing the same | |
JPH06311827A (en) | New strain of lyophyllum decastes and culture method | |
JP2523074B2 (en) | Mushroom mycelium culture method | |
KR0143511B1 (en) | Extracting hethods for separating the active comdonents contazning polysaccharive s from ganoderma lucidum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |